通过LEF1/SEMA7A/PI3K-AKT,NCAPG促进子宫内膜癌恶性进展
Zhen Ren1, Xiaohan Li1, Chun Fu1
1Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Journal of Cancer
|January 2, 2025
概括
NCAPG通过影响LEF1结合和SEMA7A转录来驱动子宫内膜癌 (EC) 的进展,最终激活PI3K-AKT通路. 这个NCAPG/LEF1/SEMA7A轴为EC提供了潜在的治疗目标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症遗传学 癌症遗传学
背景情况:
- 子宫内膜癌 (EC) 的进展与NCAPG基因有关,但其调节机制尚不清楚.
- NCAPG涉及通过PI3K-AKT通路促进EC,并显示出作为瘤标记物的潜力.
研究的目的:
- 为了阐明NCAPG在子宫内膜癌中的精确调节机制.
- 研究NCAPG/LEF1/SEMA7A轴在EC瘤发生和进展中的作用.
- 探索LEF1和SEMA7A与EC患者临床参数的相关性.
主要方法:
- 用高通量测序 (ATAC-Seq) 检测转化酶可访问染色体.
- 染色体免疫沉降-qPCR (CHIP). 染色体免疫沉降-qPCR (CHIP). 染色体免疫沉降-qPCR (CHIP). 染色体免疫沉降-qPCR.
- 共同免疫沉 (CoIP). 共同免疫沉.
主要成果:
- 通过影响LEF1染色体结合和SEMA7A转录,NCAPG促进EC细胞的增殖,迁移和入侵.
- SEMA7A通过与PI3K调节子单元p85.5结合来激活PI3K-AKT通路.
- 在NCAPG/LEF1/SEMA7A轴通过PI3K-AKT激活促进EC进展.
- LEF1和SEMA7A表达与EC阶段,等级和肌肉膜侵袭相关.
结论:
- NCAPG/LEF1/SEMA7A轴是通过PI3K-AKT通路激活而导致子宫内膜癌进展的关键驱动因素.
- LEF1和SEMA7A是EC进展和临床结果的潜在生物标志物.
- 准这种分子级联是对子宫内膜癌的有希望的治疗策略.
相关概念视频
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Tumor Progression
6.0K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.0K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Cancer Cell Migration through Invadopodia
2.2K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.2K
Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K


